Purpose: Given the emergence of PSMA-targeted diagnostic agents and therapeutics, we sought to investigate patterns of expression in RCC and their impacts on RCC outcomes.
Methods: We conducted a pooled multi-institutional analysis of patients with RCC having undergone DNA and RNA next-generation sequencing. -high/low expression was defined as the ≥75th/<25th percentile of RNA transcripts per million (TPM).